208 related articles for article (PubMed ID: 34181114)
1. The value of [68Ga]Ga-DOTA-TATE PET/CT in diagnosis and management of suspected pituitary tumors.
Novruzov F; Aliyev A; Wan MYS; Syed R; Mehdi E; Aliyeva I; Giammarile F; Bomanji JB; Kayani I
Eur J Hybrid Imaging; 2021 May; 5(1):10. PubMed ID: 34181114
[TBL] [Abstract][Full Text] [Related]
2. Development of
Shukla J; Vatsa R; Walia R; Chhabra A; Rana N; Singh H; Kumar R; Mittal BR
Cancer Biother Radiopharm; 2021 Oct; 36(8):642-650. PubMed ID: 34191604
[No Abstract] [Full Text] [Related]
3. Dual-tracer PET/CT imaging to determine tumor heterogeneity in a patient with metastatic ACTH-secreting neuroendocrine neoplasm: A case report and literature review.
Ryzhkova D; Mitrofanova L; Tsoy U; Grineva E; Schlyakhto E
Front Endocrinol (Lausanne); 2022; 13():958442. PubMed ID: 36133304
[TBL] [Abstract][Full Text] [Related]
4. Quantitative analysis of
Ma G; Du J; Zhang X; Liu J; Xu X; Xu B; Guan Z
Quant Imaging Med Surg; 2022 Apr; 12(4):2427-2440. PubMed ID: 35371938
[TBL] [Abstract][Full Text] [Related]
5. Physiological Biodistribution of
Özgüven S; Filizoğlu N; Kesim S; Öksüzoğlu K; Şen F; Öneş T; İnanır S; Turoğlu HT; Erdil TY
Mol Imaging Radionucl Ther; 2021 Feb; 30(1):39-46. PubMed ID: 33586406
[TBL] [Abstract][Full Text] [Related]
6. Gallium-68 DOTA-TATE Positron Emission Tomography/Computed Tomography: Scintigraphic Changes of Adrenal Glands Following Management of Ectopic Cushing's Syndrome by Steroidogenesis Inhibitors.
Huang YT; Aziz SI; Ravi Kumar AS
World J Nucl Med; 2014 Sep; 13(3):201-4. PubMed ID: 25538494
[TBL] [Abstract][Full Text] [Related]
7. Potential value of pre- and post-therapy [68Ga]Ga-DOTA-TATE PET/CT in the prognosis of response to PRRT in disseminated neuroendocrine tumors.
Opalińska M; Morawiec-Sławek K; Kania-Kuc A; Al Maraih I; Sowa-Staszczak A; Hubalewska-Dydejczyk A
Front Endocrinol (Lausanne); 2022; 13():929391. PubMed ID: 36046793
[TBL] [Abstract][Full Text] [Related]
8. 68Ga DOTA-TATE PET/CT allows tumor localization in patients with tumor-induced osteomalacia but negative 111In-octreotide SPECT/CT.
Breer S; Brunkhorst T; Beil FT; Peldschus K; Heiland M; Klutmann S; Barvencik F; Zustin J; Gratz KF; Amling M
Bone; 2014 Jul; 64():222-7. PubMed ID: 24769333
[TBL] [Abstract][Full Text] [Related]
9. The added value of
Kazmierczak PM; Rominger A; Wenter V; Spitzweg C; Auernhammer C; Angele MK; Rist C; Cyran CC
Eur Radiol; 2017 Apr; 27(4):1676-1684. PubMed ID: 27436022
[TBL] [Abstract][Full Text] [Related]
10. Biodistribution and first clinical results of
Ilhan H; Lindner S; Todica A; Cyran CC; Tiling R; Auernhammer CJ; Spitzweg C; Boeck S; Unterrainer M; Gildehaus FJ; Böning G; Jurkschat K; Wängler C; Wängler B; Schirrmacher R; Bartenstein P
Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):870-880. PubMed ID: 31492994
[TBL] [Abstract][Full Text] [Related]
11. Preliminary PET/CT Imaging with Somatostatin Analogs [
Satpati D; Shinto A; Kamaleshwaran KK; Sarma HD; Dash A
Mol Imaging Biol; 2017 Dec; 19(6):878-884. PubMed ID: 28349291
[TBL] [Abstract][Full Text] [Related]
12. Robust labeling and comparative preclinical characterization of DOTA-TOC and DOTA-TATE.
Velikyan I; Xu H; Nair M; Hall H
Nucl Med Biol; 2012 Jul; 39(5):628-39. PubMed ID: 22336375
[TBL] [Abstract][Full Text] [Related]
13. PET/CT With 68Ga-DOTA-TATE for Diagnosis of Neuroendocrine: Differentiation in Patients With Castrate-Resistant Prostate Cancer.
Gofrit ON; Frank S; Meirovitz A; Nechushtan H; Orevi M
Clin Nucl Med; 2017 Jan; 42(1):1-6. PubMed ID: 27775942
[TBL] [Abstract][Full Text] [Related]
14. A role for 11C-methionine PET imaging in ACTH-dependent Cushing's syndrome.
Koulouri O; Steuwe A; Gillett D; Hoole AC; Powlson AS; Donnelly NA; Burnet NG; Antoun NM; Cheow H; Mannion RJ; Pickard JD; Gurnell M
Eur J Endocrinol; 2015 Oct; 173(4):M107-20. PubMed ID: 26245763
[TBL] [Abstract][Full Text] [Related]
15. An unusual case of ectopic ACTH syndrome.
Willhauck MJ; Pöpperl G; Rachinger W; Giese A; Auernhammer CJ; Spitzweg C
Exp Clin Endocrinol Diabetes; 2012 Feb; 120(2):63-7. PubMed ID: 22187295
[TBL] [Abstract][Full Text] [Related]
16. Ga-68-DOTA-TATE PET/CT for discrimination of tumors of the optic pathway.
Klingenstein A; Haug AR; Miller C; Hintschich C
Orbit; 2015 Feb; 34(1):16-22. PubMed ID: 25264824
[TBL] [Abstract][Full Text] [Related]
17. Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours.
Haug A; Auernhammer CJ; Wängler B; Tiling R; Schmidt G; Göke B; Bartenstein P; Pöpperl G
Eur J Nucl Med Mol Imaging; 2009 May; 36(5):765-70. PubMed ID: 19137293
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-LAN PET/CT imaging in the same patient group with neuroendocrine tumours: preliminary results.
Demirci E; Ocak M; Kabasakal L; Araman A; Ozsoy Y; Kanmaz B
Nucl Med Commun; 2013 Aug; 34(8):727-32. PubMed ID: 23728519
[TBL] [Abstract][Full Text] [Related]
19.
Liu F; Zhu H; Yu J; Han X; Xie Q; Liu T; Xia C; Li N; Yang Z
Tumour Biol; 2017 Jun; 39(6):1010428317705519. PubMed ID: 28618966
[TBL] [Abstract][Full Text] [Related]
20. Semiquantitative analysis and characterization of physiological biodistribution of (68)Ga-DOTA-TATE PET/CT.
Kunikowska J; Królicki L; Pawlak D; Zerizer I; Mikołajczak R
Clin Nucl Med; 2012 Nov; 37(11):1052-7. PubMed ID: 22996234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
